Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Keyword Connections

immunogenicity
Journals
9
1 Nano letters
2 journal of pharmaceutical sciences
3 virus research
4 Vaccine
5 Future oncology (London, England)
6 antibodies (basel, switzerland)
7 World journal of clinical cases
8 viral immunology
9 jco global oncology
Research Groups
0
No Research Group Connected
Bibliographies
77
1 In Silico Methods in Antibody Design.
2 Microbial transglutaminase should be considered as an environmental inducer of celiac disease.
3 Engineering Stability, Viscosity, and Immunogenicity of Antibodies by Computational Design.
4 Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months.
5 Administration with Vaccinia Virus Encoding Canine Parvovirus 2 Elicits Systemic Immune Responses in Mice and Dogs.
6 Opportunistic Screening of Oral Potentially Malignant Disorders: A Public Health Need for India.
7 Synthesis and single-particle surface-enhanced Raman scattering study of plasmonic tripod nanoframes with Y-shaped hot-zone.
8 protective efficacy of coccidial common antigen glyceraldehyde 3-phosphate dehydrogenase (gapdh) against challenge with three eimeria species
9 listeria ivanovii infection in mice: restricted to the liver and lung with limited replication in the spleen
10 influences of combination of chemotherapy and autophagy inhibitor on the calreticulin expression in colon cancer cells
11 specific and cross-reactive immune response against mycobacterium tuberculosis antigens in mice immunized with proteoliposomes from mycobacterium bovis bcg
12 immunogenicity of anti-tnf-α biotherapies.ii. clinical relevance of methods used for anti-drug antibody detection
13 enterotoxin gene cluster-encoded sei and seln from staphylococcus aureus isolates are crucial for the induction of human blood cell proliferation and pathogenicity in rabbits
14 anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches
15 possible impact of 190g > a ccr2 and Δ32 ccr5 mutations on decrease of the hbv vaccine immunogenicity—a preliminary report
16 Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.
17 TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.
18 Assessment of the immunogenicity and protective efficiency of a novel dual-promoter DNA vaccine, harboring SAG1 and GRA7 genes, from RH strain of Toxoplasma gondii in BALB/c mice
19 Assessment of the immunogenicity and protective efficiency of a novel dual-promoter DNA vaccine, harboring SAG1 and GRA7 genes, from RH strain of Toxoplasma gondii in BALB/c mice
20 Assessment of the immunogenicity and protective efficiency of a novel dual-promoter DNA vaccine, harboring SAG1 and GRA7 genes, from RH strain of Toxoplasma gondii in BALB/c mice
21 Immunogenicity of a plasmid DNA vaccine encoding G1 epitope of bovine ephemeral fever virus G glycoprotein in mice
22 Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania
23 Development of novel subunit vaccine based on truncated fiber protein of egg drop syndrome virus and its immunogenicity in chickens.
24 A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus.
25 Immunogenicity of the Multi-Epitopic Recombinant Glycoproteins of Newcastle Disease Virus: Implications for the Serodiagnosis Applications.
26 Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates.
27 Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model
28 Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity
29 Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
30 A phase III, randomized controlled study to assess the safety and immunogenicity of a semi-synthetic diphtheria, tetanus and whole-cell pertussis vaccine in Indian infants.
31 Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process.
32 A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadravalent vaccine and their comparison with TETRAct-Hib vaccine in Indian infants aged 6-14 weeks.
33 Immunogenicity and protective efficacy of Burkholderia pseudomallei BLF1-N and BLF1-C terminal domains against BLF1 toxin.
34 Microbial Proteases in Baked Goods: Modification of Gluten and Effects on Immunogenicity and Product Quality
35 Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine.
36 A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
37 Enteropathogens and Rotavirus Vaccine Immunogenicity in a Cluster Randomized Trial of Improved Water, Sanitation and Hygiene in Rural Zimbabwe
38 The Impact of Improved Water, Sanitation, and Hygiene on Oral Rotavirus Vaccine Immunogenicity in Zimbabwean Infants: Substudy of a Cluster-randomized Trial
39 Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis.
40 Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.
41 Immunogenicity and tolerability of inactivated flu vaccine In high risk and healthy children Inmunogenicidad y tolerancia de la vacuna inactivada anti-influenza en niños en alto riesgo y en controles sanos
42 Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by instituto Butantan
43 The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response
44 Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults
45 The Impact of Improved Water, Sanitation, and Hygiene on Oral Rotavirus Vaccine Immunogenicity in Zimbabwean Infants: Substudy of a Cluster-randomized Trial
46 Immunogenicity of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod: A Double Blind Randomized Controlled Trial
47 Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60
48 Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly
49 [Safety and immunogenicity analysis of recombinant （hansenula polymorpha) hepatitis B vaccine （CpG ODN adjuvant) among adults: the preliminary results of phase I clinical trial]
50 Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old
51 Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
52 Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group
53 Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old
54 preexisting antibodies to an f(ab′)2 antibody therapeutic and novel method for immunogenicity assessment
55 immunogenicity and protective efficacy of a vero cell culture-derived whole-virus h7n9 vaccine in mice and guinea pigs.
56 disulfide isomerase erp57 improves the stability and immunogenicity of h3n2 influenza virus hemagglutinin
57 immunogenicity of a west nile virus diii-cholera toxin a2/b chimera after intranasal delivery
58 fusion tags for protein solubility, purification and immunogenicity in escherichia coli: the novel fh8 system
59 immunogenicity and safety of a chemically synthesized divalent group a streptococcal vaccine
60 tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys
61 immunogenicity of low-dose intramuscular and intradermal vaccination with recombinant hepatitis b vaccine
62 cloning, expression, and immunogenicity of fimbrial-f17a subunit vaccine against escherichia coli isolated from bovine mastitis
63 immunogenicity and safety of an as03a-adjuvanted h5n1 influenza vaccine in a taiwanese population
64 safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age
65 a review of influenza vaccine immunogenicity and efficacy in hiv-infected adults
66 segurança, imunogenicidade e eficácia da vacina contra o vírus influenza em crianças safety, immunogenicity and efficacy of influenza vaccine in children
67 a meningococcal outer membrane vesicle vaccine incorporating genetically attenuated endotoxin dissociates inflammation from immunogenicity
68 enhancement of mucosal immunogenicity of viral vectored vaccines by the nkt cell agonist alpha-galactosylceramide as adjuvant
69 immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents
70 Stable transfection of Eimeria intestinalis and investigation of its life cycle, reproduction and immunogenicity
71 High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model
72 Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
73 Long-Term Immunogenicity and Efficacy of Universal Hepatitis B Virus Vaccination in Taiwan
74 N-Glycolylated Peptidoglycan Contributes to the Immunogenicity but Not Pathogenicity of Mycobacterium tuberculosis
75 Comparison of the Immunogenicity of a Local Measles Vaccine and Other Nominal Vaccines
76 Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
77 Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study.